-
Talabostat mesylate: FAP and DPP4 Workflows
2026-09-16
Talabostat mesylate, also called PT-100, provides a practical pharmacological tool for separating DPP4- and FAP-dependent biology in tumor and immune-cell models. This guide emphasizes matched FAP-positive and FAP-negative assays, enzyme-inhibition controls, solution handling, and interpretation alongside FAP-activated vascular-disruption research.
-
Gepotidacin Assays for Bacterial DNA Replication
2026-09-15
Build a practical Gepotidacin workflow that connects enzyme inhibition, DNA damage, and whole-cell antibacterial phenotypes. The guide emphasizes solvent control, concentration design, resistant-isolate testing, and troubleshooting so GSK2140944 data remain mechanistically interpretable.
-
Leucomycin In Vitro Antibacterial Activity
2026-09-15
The 1962 study by Iwata and Akiba systematically examined leucomycin, its A1 fraction, and comparator antibiotics across pathogenic bacteria, with particular attention to erythromycin-resistant staphylococci. Its fraction-aware susceptibility design, together with tests of pH and blood effects, provides a useful historical framework for interpreting macrolide activity and planning contemporary antibacterial assays.
-
Triptolide (PG490) as a Transcriptional Probe
2026-09-14
Triptolide (PG490) is more than a potent immunosuppressive and anticancer compound: it is a practical perturbation tool for testing transcriptional dependence. This article connects its RNAPII-directed mechanism with a Xenopus pluripotency study and shows how timing, controls, and subgenome-aware readouts improve assay interpretation.
-
Cytoskeleton-Dependent Autophagy Under Compression
2026-09-14
The reference study provides direct cellular evidence that compression-induced autophagy depends strongly on cytoskeletal microfilaments, while microtubules make a supporting contribution. Its combination of mechanical loading, fluorescence imaging, western blotting, and chemical cytoskeletal perturbation offers a practical framework for studying how cells convert force into autophagy signals.
-
EZ Cap™ Firefly Luciferase mRNA: Signal Logic
2026-09-13
EZ Cap™ Firefly Luciferase mRNA (m1Ψ) is a sensitive bioluminescent reporter mRNA for separating delivery, translation, and cellular energy effects. This article adds a mechanistic framework based on recent findings about translation elongation and mRNA design.
-
PROTAC Nanoassemblies for FLASH Radiosensitization
2026-09-12
This study develops a folate-targeted, redox-responsive PROTAC nanoassembly that degrades BRD4 and strengthens FLASH radiotherapy by impairing DNA repair while increasing oxidative and double-strand damage. The findings support targeted protein degradation as a strategy for overcoming tumor radioresistance, although broader validation is needed beyond the reported model.
-
N3-kethoxal Workflows for RNA and ssDNA Mapping
2026-09-12
N3-kethoxal converts transiently unpaired guanines in RNA and single-stranded DNA into stable, azide-bearing molecular handles. Use it to connect live-cell labeling, RNA secondary structure probing, and KAS-ATAC-style genomic enrichment with bioorthogonal click chemistry.
-
XAV-939 (NVP-XAV939): Wnt Pathway Tool
2026-09-11
XAV-939, also called NVP-XAV939, is a cell-permeable TNKS1/TNKS2 inhibitor that stabilizes axin and suppresses β-catenin signaling. Its documented research uses include osteogenic differentiation, cancer research, and bleomycin-induced fibrosis models.
-
Toremifene Workflows for Prostate Cancer Research
2026-09-11
Build more informative hormone-responsive cancer assays by pairing Toremifene-mediated estrogen receptor modulation with growth, calcium-flux, and metastatic-behavior readouts. This workflow uses the TSPAN18–STIM1 findings as a hypothesis-generating framework while clearly separating established product performance from experimental recommendations.
-
ω-Agatoxin IVA Suppresses Seizures in Rats
2026-09-10
This rat study identifies selective P/Q-type calcium channel blockade with ω-agatoxin IVA as a way to delay seizure onset, suppress chemical kindling, and reduce epileptic discharges without detectable motor-coordination impairment. Its neurobiological contribution is the parallel association of Cav2.1 inhibition with increased BDNF and reduced cleaved caspase-3 expression across several brain regions.
-
HDAC Inhibition Reverses EBV-Driven NPC Dedifferentiation
2026-09-10
The reference study identifies an EBV-LMP1–STAT5A–HDAC1/2–CEBPA pathway that drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma. Its xenograft data support HDAC inhibition as a preclinical differentiation strategy, while also defining experimental controls needed to distinguish cell-state reversal from nonspecific cytotoxicity.
-
VX-765 for Reliable Caspase-1 Assays
2026-09-09
This scenario-based guide explains how VX-765, Caspase-1 inhibitor, potent and selective (SKU A8238), can improve mechanistic interpretation in viability, proliferation, cytokine-release, and pyroptosis experiments. It covers assay design, stock preparation, data interpretation, and practical vendor-selection criteria.
-
Q-VD-OPh and the Dynamic Apoptosome
2026-09-09
Q-VD-OPh is a cell-permeable pan-caspase inhibitor for dissecting when apoptosome formation becomes irreversible cell death. This article connects inhibitor timing, live-cell Apaf1 imaging, and assay interpretation for more rigorous apoptosis research.
-
Pseudo-UTP for Better mRNA Synthesis
2026-09-08
Pseudo-UTP enables controlled pseudouridine incorporation for mRNA synthesis, with practical value in translation, RNA stability enhancement, and immunogenicity studies. This workflow connects nucleotide selection with antigen-design lessons from recent MERS-CoV mRNA research while emphasizing matched controls and assay-specific optimization.